We present 3 cases of pseudoallergic (anaphylactoid) reactions to perioperatively administered rocuronium, which rapidly resolved after sugammadex injection. Allergological workup showed no evidence for immediate-type hypersensitivity to the drugs used for anesthesia, including rocuronium. However, rocuronium induced an irritative reaction in skin tests in all 3 patients and in 3 healthy individuals. This reaction was specifically suppressed by adding sugammadex at a 1:1 molecular proportion to rocuronium before the skin tests. This observation suggests that the patients suffered from a pseudoallergic reaction, and indicates that sugammadex might act via the inhibition of non-IgE mediated MRGPRX2 (Mas-related G-protein-coupled receptor member X2)-triggered mast cell degranulation induced by rocuronium.

Keywords:
Anaphylaxis, Anaphylactoid reaction, Rocuronium, Sugammadex, Receptor
1.
Dong SW, Mertes PM, Petitpain N, Hasdenteufel F, Malinovsky JM; GERAP: Hypersensitivity reactions during anesthesia: results from the ninth French survey (2005-2007). Minerva Anestesiol 2012;78:868-878.
2.
Florvaag E, Johansson SG, Oman H, Venemalm L, Degerbeck F, Dybendal T, Lundberg M: Prevalence of IgE antibodies to morphine: relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005;49:437-444.
3.
Johansson SG, Florvaag E, Oman H, Poulsen LK, Mertes PM, Harper NJ, Garvey LH, Gerth van Wijk R, Metso T, Irgens A, Dybendal T, Halsey J, Seneviratne SL, Guttormsen AB: National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010;65:498-502.
4.
Rouzaire P, Nosbaum A, Mullet C, Diot N, Dubost R, Bienvenu F, Guilloux L, Piriou V, Bienvenu J, Berard F: Immediate allergic hypersensitivity to quinolones associates with neuromuscular blocking agent sensitization. J Allergy Clin Immunol Pract 2013;1:273-279.e1.
5.
Bom A, Bradley M, Cameron K, Clark JK, van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ: A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002;41:266-270.
6.
Harper NJ, Dixon T, Dugue P, Edgar DM, Fay A, Gooi HC, Herriot R, Hopkins P, Hunter JM, Mirakian R, Pumphrey RS, Seneviratne SL, Walls AF, Williams P, Wildsmith JA, Wood P, Nasser AS, Powell RK, Mirakhur R, Soar J; Working Party of the Association of Anaesthetists of Great Britain and Ireland: Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009;64:199-211.
7.
Mertes PM, Moneret-Vautrin DA, Leynadier F, Laxenaire MC: Skin reactions to intradermal neuromuscular blocking agent injections: a randomized multicenter trial in healthy volunteers. Anesthesiology 2007;107:245-252.
8.
Dhonneur G, Combes X, Chassard D, Merle JC: Skin sensitivity to rocuronium and vecuronium: a randomized controlled prick-testing study in healthy volunteers. Anesth Analg 2004;98:986-989.
9.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al: Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-712.
10.
Ebo DG, Venemalm L, Bridts CH, Degerbeck F, Hagberg H, De Clerck LS, Stevens WJ: Immunoglobulin E antibodies to rocuronium: a new diagnostic tool. Anesthesiology 2007;107:253-259.
11.
Schaller SJ, Fink H: Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid 2013;8:57-67.
12.
Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M, World Allergy Organization: World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013;162:193-204.
13.
Czarnetzki C, Tassonyi E, Lysakowski C, Elia N, Tramer MR: Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial. Anesthesiology 2014;121:59-67.
14.
Platt PR, Clarke RC, Johnson GH, Sadleir PH: Efficacy of sugammadex in rocuronium-induced or antibiotic-induced anaphylaxis: a case-control study. Anaesthesia 2015;70:1264-1267.
15.
Bjornsson HM, Graffeo CS: Improving diagnostic accuracy of anaphylaxis in the acute care setting. West J Emerg Med 2010;11:456-461.
16.
Dybendal T, Guttormsen AB, Elsayed S, Askeland B, Harboe T, Florvaag E: Screening for mast cell tryptase and serum IgE antibodies in 18 patients with anaphylactic shock during general anaesthesia. Acta Anaesthesiol Scand 2003;47:1211-1218.
17.
Krishna MT, Huissoon A: Peri-operative anaphylaxis: beyond drugs and latex. Int Arch Allergy Immunol 2015;167:101-102.
18.
McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X: Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237-241.
19.
Baldo BA, McDonnell NJ, Pham NH: Drug-specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allergy 2011;41:1663-1678.
20.
Jones PM, Turkstra TP: Mitigation of rocuronium-induced anaphylaxis by sugammadex: the great unknown. Anaesthesia 2010;65:89-90.
21.
Badaoui R, Popov I, Dupont H: A case of rocuronium-induced anaphylactic shock, improved by sugammadex (in French). Can J Anaesth 2012;59:909-910.
22.
Funnell AE, Griffiths J, Hodzovic I: A further case of rocuronium-induced anaphylaxis treated with sugammadex. Br J Anaesth 2011;107:275-276.
23.
Kawano T, Tamura T, Hamaguchi M, Yatabe T, Yamashita K, Yokoyama M: Successful management of rocuronium-induced anaphylactic reactions with sugammadex: a case report. J Clin Anesth 2012;24:62-64.
24.
McDonnell NJ, Pavy TJ, Green LK, Platt PR: Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth 2011;106:199-201.
25.
Raft J, Leclercq M, Longrois D, Meistelman C: Fast recovery of haemodynamic and ventilatory functions after sugammadex bolus following rocuronium-induced anaphylactic shock refractory to conventional treatment (in French). Ann Fr Anesth Reanim 2012;31:158-161.
26.
Motamed C, Baguenard P, Bourgain JL: Possible mitigation of rocuronium-induced anaphylaxis after administration of sugammadex. J Anaesthesiol Clin Pharmacol 2012;28:127-128.
27.
Barthel F, Stojeba N, Lyons G, Biermann C, Diemunsch P: Sugammadex in rocuronium anaphylaxis: dose matters. Br J Anaesth 2012;109:646-647.
28.
Sirieix D, Latreille S, Raft J: Rapid hemodynamic recovery after early epinephrine and sugammadex co-administration during rocuronium-induced anaphylactic reaction (in French). Ann Fr Anesth Reanim 2014;33:602-603.
29.
Leysen J, Bridts CH, de Clerck LS, Ebo DG: Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an in vitro experiment. Anaesthesia 2011;66:526-527.
30.
Clarke RC, Sadleir PH, Platt PR: The role of sugammadex in the development and modification of an allergic response to rocuronium: evidence from a cutaneous model. Anaesthesia 2012;67:266-273.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.